A curated list of research papers related to opioid treatment can be navigated using the box on the right called "Table of Contents."
Davis MP. Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother. 2011;11(8):1197-1216.
Drewes AM, Jensen RD, Nielsen LM, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol. 2013;75(1):60-78.
Hansen MS, Dahl JB. Limited evidence for intranasal fentanyl in the emergency department and the prehospital setting--a systematic review. Dan Med J. 2013;60(1):A4563.
Hansen MS, Mathiesen O, Trautner S, Dahl JB. Intranasal fentanyl in the treatment of acute pain--a systematic review. Acta Anaesthesiol Scand. 2012;56(4):407-419.
Paech MJ, Bloor M, Schug SA. New formulations of fentanyl for acute pain management. Drugs Today. 2012;48(2):119-132.
Staahl C, Olesen AE, Andresen T, Arendt-Nielsen L, Drewes AM. Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review. Br J Clin Pharmacol. 2009;68(2):149-168.
Coffey RJ, Owens ML, Broste SK, et al. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain. Pain Med. 2010;11(7):1001-1009.
Manchikanti L, Falco FJE, Singh V, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part I: introduction and general considerations. Pain Physician. 2013;16(2 Suppl):S1-48.
Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. Pain Physician. 2013;16(2 Suppl):S49-283.
Argoff C. NSAIDs or opioids, damned if you do, damned if you don’t?: evidence-based selections to optimize therapeutic goals and minimize harms. Pain Med. 2013;14 Suppl 1:S40-42.
Bruehl S, Apkarian AV, Ballantyne JC, et al. Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain. 2013;14(2):103-113.
Basurto Ona X, Rigau Comas D, Urrútia G. Opioids for acute pancreatitis pain. Cochrane Database Syst Rev. 2013;7:CD009179.
Branford R, Droney J, Ross JR. Opioid genetics: the key to personalized pain control? Clin Genet. 2012;82(4):301-310.
Chaparro LE, Smith SA, Moore RA, Wiffen PJ, Gilron I. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst Rev. 2013;7:CD008307.
Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev. 2013;8:CD004959.
Finco G, Pintor M, Sanna D, et al. Is target opioid therapy within sight? Minerva Anestesiol. 2012;78(4):462-472.
Haroutiunian S, McNicol ED, Lipman AG. Methadone for chronic non-cancer pain in adults. Cochrane Database Syst Rev. 2012;11:CD008025.
Kirsh KL, Fishman SM. Multimodal approaches to optimize outcomes of chronic opioid therapy in the management of chronic pain. Pain Med. 2011;12 Suppl 1:S1-11.
Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clin Drug Investig. 2012;32 Suppl 1:53-63.
McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;8:CD006146.
Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72(2):181-190.
Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011;80(3):460-465.
Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236-2247.
Stamer UM, Zhang L, Stüber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics. 2010;11(6):843-864.
Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet. 2011;377(9784):2226-2235.
Whittle SL, Richards BL, Husni E, Buchbinder R. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev. 2011;(11):CD003113.
Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2013;7:CD003868.
Prescription Opioid Abuse
Edwards RR, Wasan AD, Michna E, Greenbaum S, Ross E, Jamison RN. Elevated pain sensitivity in chronic pain patients at risk for opioid misuse. J Pain. 2011;12(9):953-963. doi.
Gourlay DL, Heit HA. Pain and addiction: managing risk through comprehensive care. J Addict Dis. 2008;27(3):23-30.
Gudin JA. Clinical strategies for the primary health care professional to minimize prescription opioid abuse. Postgrad Med. 2012;124(3):131-138.
Jamison RN, Ross EL, Michna E, Chen LQ, Holcomb C, Wasan AD. Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial. Pain. 2010;150(3):390-400.
McCarberg BH. Pain management in primary care: strategies to mitigate opioid misuse, abuse, and diversion. Postgrad Med. 2011;123(2):119-130.
Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84(7):593-601.
Peng P, Tumber P, Stafford M, et al. Experience of methadone therapy in 100 consecutive chronic pain patients in a multidisciplinary pain center. Pain Med. 2008;9(7):786-794 .
Wasan AD, Ross EL, Michna E, et al. Craving of prescription opioids in patients with chronic pain: a longitudinal outcomes trial. J Pain. 2012;13(2):146-154.
Jamison RN, Edwards RR, Liu X, et al. Relationship of negative affect and outcome of an opioid therapy trial among low back pain patients. Pain Pract. 2013;13(3):173-181.
Michna E, Cheng WY, Korves C, et al. Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management. Pain Med. 2014;15(1):79-92.
Fitzgibbon DR, Rathmell JP, Michna E, Stephens LS, Posner KL, Domino KB. Malpractice claims associated with medication management for chronic pain. Anesthesiology. 2010;112(4):948-956.
Gilson AM, Maurer MA, Lebaron VT, Ryan KM, Cleary JF. Multivariate analysis of countries’ government and health-care system influences on opioid availability for cancer pain relief and palliative care: more than a function of human development. Palliat Med. 2013;27(2):105-114.
Gilson AM, Maurer MA, Ryan KM, Skemp-Brown M, Husain A, Cleary JF. Ensuring patient access to essential medicines while minimizing harmful use: a revised World Health Organization tool to improve national drug control policy. J Pain Palliat Care Pharmacother. 2011;25(3):246-251.
Rich BA, Webster LR. A review of forensic implications of opioid prescribing with examples from malpractice cases involving opioid-related overdose. Pain Med. 2011;12 Suppl 2:S59-65.
Wilhelmi BG, Cohen SP. A framework for “driving under the influence of drugs” policy for the opioid using driver. Pain Physician. 2012;15(3 Suppl):ES215-230.
Wilsey BL, Fishman SM, Gilson AM, et al. An Analysis of the Number of Multiple Prescribers for Opioids Utilizing Data from the California Prescription Monitoring Program. Pharmacoepidemiol Drug Saf. 2011;20(12):1262-1268.
Butler SF, Benoit C, Budman SH, et al. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J. 2006;3:5.
McCarberg BH. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse. Postgrad Med. 2011;123(6):132-139.
Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15(3 Suppl):ES67-92.
Urine Drug Toxicology
Comer SD, Zacny JP, Dworkin RH, et al. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain. 2012;153(12):2315-2324.
Nafziger AN, Bertino JS Jr. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain. 2009;25(1):73-79.
Peppin JF, Passik SD, Couto JE, et al. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med. 2012;13(7):886-896.
Abuse Deterrent Formulations
Argoff CE, Stanos SP, Wieman MS. Validity testing of patient objections to acceptance of tamper-resistant opioid formulations. J Pain Res. 2013;6:367-373.
Turk DC, O’Connor AB, Dworkin RH, et al. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain. 2012;153(10):1997-2008.